Since the well-established downstream effector miR-34a of p53 is known to inhibit the IL6R/STAT3/miR-34a feedback loop, a potential p53-mediated decrease of miR-34a may in turn lead to activation of IL6R/STAT3 signaling and thus CRC progression [49]. The gene discussed is TP53; the disease is colorectal carcinoma.